BTK Inhibitor Ibrutinib may give protection against pulmonary inflammation

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243149/

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Steven P. Treon,1,1,2 Jorge J. Castillo,1,2 Alan P. Skarbnik,3 et al

Links to other related articles and papers:

https://cllsociety.org/2020/07/covid-19-severity-and-mortality-in-chronic-lymphocytic-leukemia-cll-patients/

https://cllsociety.org/2020/04/ibrutinib-and-acalabrutinib-for-covid-19/

https://www.nature.com/articles/s41375-020-0959-x

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

•         Lydia Scarfò, Thomas Chatzikonstantinou, […]Paolo Ghia 

AZ Clinical Trial of Acalabrutinib

https://www.astrazeneca-us.com/content/az-us/media/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19-04142020.html